Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab’s OX40 candidate

The latest from pharma, biotech and healthcare

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

- PMLiVE

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

News from pharma, biotech and healthcare

- PMLiVE

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

Speech coincides with Biosimilars Action Plan

Novartis day

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

A round up from pharma, biotech and healthcare

- PMLiVE

Novartis follows Pfizer and freezes US prices this year

And still expects revenues to come in at the high end of expectations for 2018

Novartis launch NET cancer community app

Galaxies of Hope aims to provide support to cancer patients

- PMLiVE

Novartis rejects claims it misled Senate over Cohen links

Report says Novartis discussed drug-pricing with the President’s former ‘fixer’

- PMLiVE

Some pharma companies not prepared for Brexit, warns EMA

Regulator concerned about medicines shortages after March 2019

- PMLiVE

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

A round up from pharma, biotech and healthcare

- PMLiVE

Alcon spin-off prompts Novartis downgrade by Moody’s

Selling off Alcon concentrates business in riskier areas

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links